Medication overuse headache: History, features, prevention and management strategies

CNS Drugs

Volumn 27, Issue 11, 2013, Pages 867-877

  Saper, Joel R ^a   Da Silva, Arnaldo Neves ^a  

^a Michigan Head Pain and Neurological Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; BUTALBITAL; DECONGESTIVE AGENT; DIHYDROERGOTAMINE; DIPHENHYDRAMINE; DROPERIDOL; ERGOTAMINE TARTRATE; KETOROLAC; MAGNESIUM; METOCLOPRAMIDE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PROCHLORPERAZINE; STEROID; TRIPTAN DERIVATIVE; VALPROIC ACID;

ARTICLE; BEHAVIOR DISORDER; CHRONIC DAILY HEADACHE; CLINICAL FEATURE; CLINICAL PRACTICE; DRUG ABUSE; DRUG INDUCED HEADACHE; DSM-IV; EPISODIC MIGRAINE; HEALTH CARE POLICY; HUMAN; INCIDENCE; MIGRAINE; MIGRAINE WITHOUT AURA; OUTPATIENT; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY HEADACHE; PRIORITY JOURNAL; RECIDIVISM; SYMPTOMATOLOGY; TENSION HEADACHE; TRANSFORMED MIGRAINE; ULCERATIVE COLITIS;

ANALGESICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG OVERDOSE; HEADACHE DISORDERS, SECONDARY; HUMANS; INCIDENCE; META-ANALYSIS AS TOPIC; PREVALENCE; TIME FACTORS;

EID: 84887081970     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0081-y     Document Type: Article

References (73)

1. Kudrow L. Paradoxical effects of frequent analgesic use. Adv Neurol. 1982;33:335-41.
2. Saper JR. Drug abuse among headache patients. In: Headache disorders: current concepts and treatment strategies. USA: John Wright; 1983. p. 263-78.
3. Saper JR. Migraine. I. classification and pathogenesis. JAMA. 1978;239(22):2380-3.
4. Isler H. Headaches combined with overuse of analgesics. In: Carrol JD, Pfaffenrath V, Sjaastad O, editors. Migraine and beta-blockade. Molndal (Sweeden): Hassle; 1985. p. 180-3.
5. Rowsell AR, Neylan C, Wilkinson M. Ergotamine induced headaches in migrainous patients. Headache. 1973;13(2):65-7.
6. Saper JR. Migraine: II. Treatment. JAMA. 1978;239(23):2480-4.
7. Rapoport AM, Sheftell FD, Weeks RE, Baskin SM. Analgesic rebound headache. In: Proceedings of the Twelfth Meeting of the Scandinavian Migraine Society. 1983. p. 37-38.
8. Saper JR, Jones JM. Ergotamine tartrate dependency: features and possible mechanisms. Clin Neuropharmacol. 1986;9(3):244-56.
9. Ferraro S, Grazzi L, Muffatti R, Nava S, Ghielmetti F, Bertolino N, et al. In medication-overuse headache, fMRI shows long-lasting dysfunction in midbrain areas. Headache. 2012;52(10):1520-34.
10. Headache Classification Committee; Olesen J, Bousser MG, Diener HC, Dodick D, First M, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26(6):742-6.
11. Saper JR, Lake AE, 3rd. Medication overuse headache: type I and type II. Cephalalgia. 2006;26(10):1262.
12. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157-68.
13. De Felice M, Ossipov MH, Porreca F. Update on medication-overuse headache. Curr Pain Headache Rep. 2011;15(1):79-83.
14. De Felice M, Ossipov MH, Wang R, Lai J, Chichorro J, Meng I, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol. 2010;67(3):325-37.
15. Tepper SJ. Medication-overuse headache. Continuum (Minneapolis Minn). 2012;18(4):807-22.
16. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001;57(9):1694-8.
17. Katsarava Z, Jensen R. Medication-overuse headache: where are we now? Curr Opin Neurol. 2007;20(3):326-30.
18. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002;59(7):1011-4.
19. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache. 2003;43(3):179-90.
20. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001;41(3):303-9.
21. Waeber C, Moskowitz MA. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology. 2003;61(8 Suppl 4):S9-20.
22. Calabresi P, Cupini LM. Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci. 2005;26(2):62-8.
23. Diener HC, Dahlof CGH. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The Headaches, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins; 1999. p. 671-878.
24. Castillo J, Munoz P, Guitera V, Pascual J. Kaplan award 1998. Epidemiology of chronic daily headache in the general population. Headache. 1999;39(3):190-6.
25. Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology. 2009;72(5 Suppl):S3-7.
26. Ghiotto N, Sances G, Galli F, Tassorelli C, Guaschino E, Sandrini G, et al. Medication overuse headache and applicability of the ICHD-II diagnostic criteria: 1-year follow-up study (CARE I protocol). Cephalalgia. 2009;29(2):233-43.
27. Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep. 2001;5(6):529-36.
28. Rapoport A, Stang P, Gutterman DL, Cady R, Markley H, Weeks R, et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache. 1996;36(1):14-9.
29. Russell MB, Lundqvist C. Prevention and management of medication overuse headache. Curr Opin Neurol. 2012;25(3):290-5.
30. Piazza F, Chiappedi M, Maffioletti E, Galli F, Balottin U. Medication overuse headache in school-aged children: more common than expected? Headache. 2012;52(10):1506-10.
31. Saper JR, Hamel RL, Lake AE 3rd. Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia. 2005;25(7):545-6.
32. Fuh JL, Wang SJ, Lu SR, Juang KD. Does medication overuse headache represent a behavior of dependence? Pain. 2005;119(1-3):49-55.
33. Saper JR, Lake AE 3rd. Borderline personality disorder and the chronic headache patient: review and management recommendations. Headache. 2002;42(7):663-74.
34. Srikiatkhachorn A, Puangniyom S, Govitrapong P. Plasticity of 5-HT serotonin receptor in patients with analgesic-induced transformed migraine. Headache. 1998;38(7):534-9.
35. Srikiatkhachorn A, Tarasub N, Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache. 2000;40(5):343-50.
36. Pini LA, Sandrini M, Vitale G. The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Eur J Pharmacol. 1996;308(1):31-40.
37. Bjorkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol: experimental studies in the rat. Acta Anaesthesiol Scand Suppl. 1995;103:1-44.
38. Supornsilpchai W, le Grand SM, Srikiatkhachorn A. Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia. 2010;30(9):1101-9.
39. Saper JR, Lake AE 3rd, Bain PA, Stillman MJ, Rothrock JF, Mathew NT, et al. A practice guide for continuous opioid therapy for refractory daily headache: patient selection, physician requirements, and treatment monitoring. Headache. 2010;50(7):1175-93.
40. De Felice M, Porreca F. Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. Cephalalgia. 2009;29(12):1277-84.
41. Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep. 2006;10(1):67-70.
42. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: novel counter-regulators of opioid analgesia. Trends Neurosci. 2005;28(12):661-9.
43. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24(8):450-5.
44. De Felice M, Ossipov MH, Wang R, Dussor G, Lai J, Meng ID, et al. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain. 2010;133(Pt 8):2475-88.
45. Fumal A, Laureys S, Di Clemente L, Boly M, Bohotin V, Vandenheede M, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain. 2006;129(Pt 2):543-50.
46. Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005;45(7):850-61.
47. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804-14.
48. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814-23.
49. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170-80.
50. Rabe K, Pageler L, Gaul C, Lampl C, Kraya T, Foerderreuther S, et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2013;33(3):202-7.
51. Swidan SZ, Lake AE 3rd, Saper JR. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache. Curr Pain Headache Rep. 2005;9(1):65-70.
52. Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache. 1990;30(6):334-9.
53. Ford RG, Ford KT. Continuous intravenous dihydroergotamine in the treatment of intractable headache. Headache. 1997;37(3):129-36.
54. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36(7):995-7.
55. Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827-32.
56. Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002;23(2):141-8.
57. Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004;329(7479):1369-73.
58. Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA. 1989;261(8):1174-6.
59. Miner JR, Fish SJ, Smith SW, Biros MH. Droperidol vs. prochlorperazine for benign headaches in the emergency department. Acad Emerg Med. 2001;8(9):873-9.
60. Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache. 2002;42(6):519-22.
61. Mathew NT, Kailasam J, Meadors L, Chernyschev O, Gentry P. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache. 2000;40(9):720-3.
62. Shrestha M, Singh R, Moreden J, Hayes JE. Ketorolac vs chlorpromazine in the treatment of acute migraine without aura: a prospective, randomized, double-blind trial. Arch Intern Med. 1996;156(15):1725-8.
63. Demirkaya S, Vural O, Dora B, Topcuoglu MA. Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache. 2001;41(2):171-7.
64. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2002;22(5):345-53.
65. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache. 1996;36(3):154-60.
66. Donaldson D, Sundermann R, Jackson R, Bastani A. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial. Am J Emerg Med. 2008;26(2):124-30.
67. Fiesseler FW, Shih R, Szucs P, Silverman ME, Eskin B, Clement M, et al. Steroids for migraine headaches: a randomized double-blind, two-armed, placebo-controlled trial. J Emerg Med. 2011;40(4):463-8.
68. Munksgaard SB, Bendtsen L, Jensen RH. Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: a comparison of two consecutive treatment methods in an open-label design. Cephalalgia. 2012;32(11):834-44.
69. Creac'h C, Frappe P, Cancade M, Laurent B, Peyron R, Demarquay G, et al. In-patient versus out-patient withdrawal programmes for medication overuse headache: a 2-year randomized trial. Cephalalgia. 2011;31(11):1189-98.
70. Lake AE 3rd, Saper JR, Hamel RL. Comprehensive inpatient treatment of refractory chronic daily headache. Headache. 2009;49(4):555-62.
71. Zed PJ, Loewen PS, Robinson G. Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother. 1999;33(1):61-72.
72. Hagen K, Albretsen C, Vilming ST, Salvesen R, Gronning M, Helde G, et al. A 4-year follow-up of patients with medication-overuse headache previously included in a randomized multicentre study. J Headache Pain. 2011;12(3):315-22.
73. Rossi P, Faroni JV, Nappi G. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia. 2008;28(11):1196-200.